Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults

被引:180
作者
Clements-Mann, ML
Weinhold, K
Matthews, TJ
Graham, BS
Gorse, GJ
Keefer, MC
McElrath, MJ
Hsieh, RH
Mestecky, J
Zolla-Pazner, S
Mascola, J
Schwartz, D
Siliciano, R
Corey, L
Wright, PF
Belshe, R
Dolin, R
Jackson, S
Xu, S
Fast, P
Walker, MC
Stablein, D
Excler, JL
Tartaglia, J
Duliege, AM
Sinangil, F
Paoletti, E
机构
[1] Johns Hopkins Univ, Sch Publ Hlth, Baltimore, MD USA
[2] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[3] EMMES Corp, Potomac, MD USA
[4] NIAID, Div Aids, NIH, Bethesda, MD 20892 USA
[5] Duke Univ, Sch Med, Durham, NC USA
[6] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA
[7] St Louis Univ, Sch Med, St Louis, MO USA
[8] Vet Adm Med Ctr, St Louis, MO USA
[9] Univ Rochester, Sch Med & Dent, Rochester, NY USA
[10] Vet Adm Med Ctr, New York, NY 10010 USA
[11] NYU Med Ctr, New York, NY 10016 USA
[12] Virogenet Corp, Troy, NY 12180 USA
[13] Univ Washington, Sch Med, Seattle, WA USA
[14] Walter Reed Army Inst Res, Washington, DC USA
[15] Chiron Vaccines, Emeryville, CA USA
[16] Pasteur Merieux Connaught, Marnes la Coquette, France
关键词
D O I
10.1086/515288
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A safety and immunogenicity trial was conducted in vaccinia-immune and vaccinia-naive human immunodeficiency virus (HIV)-uninfected adults who were randomized to receive 10(6) or 10(7) TCID50 of canarypox (ALVAC) vector expressing HIV-1(MN) gp160 or 10(5.5) TCID50 of ALVAC-rabies virus glycoprotein control at 0 and 1 or 2 months and ALVAC-gp160 or 50 mu g of HIV-1(SF2) recombinant (r) gp12O in microfluidized emulsion at 9 and 12 months; others received rgp120 at 0, 1, 6, and 12 months. All vaccines were well-tolerated. Neither vaccinia-immune status before vaccination nor ALVAC dose affected HIV immune responses. HIV-1(MN) and HIV-1(SF2) neutralizing antibodies were detected more often (100%) in ALVAC-gp160/rgp120 recipients than in recipients of ALVAC-gp160 (<65%) or rgp120 (89%) alone. ALVAC-gp160/rgp120 also elicited more frequent HIV V3-specific and fusion-inhibition antibodies, antibody-dependent cellular cytotoxicity, lymphoproliferation, and cytotoxic CD8(+) T cell activity than did either vaccine alone. Trials with ALVAC expressing additional HIV components and rgp120 are underway.
引用
收藏
页码:1230 / 1246
页数:17
相关论文
共 79 条
[1]  
ALDHOUS MC, 1994, CLIN EXP IMMUNOL, V97, P61
[2]   Immunogenicity and protective efficacy of a human immunodeficiency virus type 2 recombinant canarypox (ALVAC) vaccine candidate in cynomolgus monkeys [J].
Andersson, S ;
Makitalo, B ;
Thorstensson, R ;
Franchini, G ;
Tartaglia, J ;
Limbach, K ;
Paoletti, E ;
Putkonen, P ;
Biberfeld, G .
JOURNAL OF INFECTIOUS DISEASES, 1996, 174 (05) :977-985
[3]   MULTIPLE INTRODUCTIONS OF HIV-1 SUBTYPE-E INTO THE WESTERN-HEMISPHERE [J].
ARTENSTEIN, AW ;
COPPOLA, J ;
BROWN, AE ;
CARR, JK ;
SANDERSBUELL, E ;
GALBARINI, E ;
MASCOLA, JR ;
VANCOTT, TC ;
SCHONBROOD, P ;
MCCUTCHAN, FE ;
BURKE, DS .
LANCET, 1995, 346 (8984) :1197-1198
[4]   POTENTIAL USE OF NONREPLICATING VECTORS AS RECOMBINANT VACCINES [J].
BAXBY, D ;
PAOLETTI, E .
VACCINE, 1992, 10 (01) :8-9
[5]   SAFETY AND IMMUNOGENICITY OF A FULLY GLYCOSYLATED RECOMBINANT GP160 HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 VACCINE IN SUBJECTS AT LOW-RISK OF INFECTION [J].
BELSHE, RB ;
CLEMENTS, ML ;
DOLIN, R ;
GRAHAM, BS ;
MCELRATH, J ;
GORSE, GJ ;
SCHWARTZ, D ;
KEEFER, MC ;
WRIGHT, P ;
COREY, L ;
BOLOGNESI, DP ;
MATTHEWS, TJ ;
STABLEIN, DM ;
OBRIEN, FS ;
EIBL, M ;
DORNER, F ;
KOFF, W .
JOURNAL OF INFECTIOUS DISEASES, 1993, 168 (06) :1387-1395
[6]   Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1 [J].
Berman, PW ;
Murthy, KK ;
Wrin, T ;
Vennari, JC ;
Cobb, EK ;
Eastman, DJ ;
Champe, M ;
Nakamura, GR ;
Davison, D ;
Powell, MF ;
Bussiere, J ;
Francis, DP ;
Matthews, T ;
Gregory, TJ ;
Obijeski, JF .
JOURNAL OF INFECTIOUS DISEASES, 1996, 173 (01) :52-59
[7]   PROTECTION OF CHIMPANZEES FROM INFECTION BY HIV-1 AFTER VACCINATION WITH RECOMBINANT GLYCOPROTEIN GP120 BUT NOT GP160 [J].
BERMAN, PW ;
GREGORY, TJ ;
RIDDLE, L ;
NAKAMURA, GR ;
CHAMPE, MA ;
PORTER, JP ;
WURM, FM ;
HERSHBERG, RD ;
COBB, EK ;
EICHBERG, JW .
NATURE, 1990, 345 (6276) :622-625
[8]   VIRUS-SPECIFIC CD8+ CYTOTOXIC T-LYMPHOCYTE ACTIVITY ASSOCIATED WITH CONTROL OF VIREMIA IN PRIMARY HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION [J].
BORROW, P ;
LEWICKI, H ;
HAHN, BH ;
SHAW, GM ;
OLDSTONE, MBA .
JOURNAL OF VIROLOGY, 1994, 68 (09) :6103-6110
[9]  
Brandtzaeg P, 1970, Scand J Haematol Suppl, V12, P3
[10]   HIV-1 ENVELOPE-ELICITED NEUTRALIZING ANTIBODY-TITERS CORRELATE WITH PROTECTION AND VIRUS LOAD IN CHIMPANZEES [J].
BRUCK, C ;
THIRIART, C ;
FABRY, L ;
FRANCOTTE, M ;
PALA, P ;
VANOPSTAL, O ;
CULP, J ;
ROSENBERG, M ;
DEWILDE, M ;
HEIDT, P ;
HEENEY, J .
VACCINE, 1994, 12 (12) :1141-1148